Pembrolizumab (Keytruda) is a targeted therapy used to treat a wide range of tumors. Unfortunately, it can have a negative impact on a fetus.

Mechanism: humanized monoclonal antibody


Target: PD-1/PD-L1


Blocking of PD-1/PD-L1 cause T cells to target tumor cells. Blockade may also cause T-cells to attack normal host cells (autoimmune reaction).


Adverse effects of pembrolizumab on a fetus:

(1) increased risk of abortion or stillbirth

(2) altered immune function with potential for immune-mediated disorders


Congenital malformations have not been described.


A woman who is in her reproductive years should use an effective method of contraception.

To read more or access our algorithms and calculators, please log in or register.